Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOSHealthcare · Biotechnology
-90.83%$0.2101
AH$0.2226+5.95%vs close
Mkt Cap$15.2M
Float45.63M
O/S72.33M
Vol
$ Vol
RVOL
Inst Own66.1%
SI6.8%
Earnings
Dilution
1-25 of 364 filings
…
Recent SEC filings with analysis
- S-3Acumen Pharmaceuticals filed a new Form S-3 universal shelf registration on October 26, 2026, allowing it to offer up to $500 million of common stock,…
- 10-QAcumen Pharmaceuticals reported a Q3 2026 net loss of $25.4 million and a nine-month net loss of $78.8 million, with $78.6 million in cash and marketable…
- 8-KAcumen Pharmaceuticals reported Q3 2026 results with a net loss of $25.4 million and cash of $78.6 million, down from $110.2 million at the end of June.